Kidas Ekaterini, Möricke Anja, Beier Rita, Welte Karl, Schrappe Martin, Stanulla Martin, Grigull Lorenz
Department of Paediatric Haematology and Oncology, OE 6780, Medizinische Hochschule Hannover, Hannover, Germany.
Int J Hematol. 2009 Jun;89(5):584-91. doi: 10.1007/s12185-009-0285-6. Epub 2009 Apr 8.
Specific mutations of the TNF-alpha (TNF-alpha) and Lymphotoxin-alpha (LT-alpha) genes are correlated to the outcome of patients during serious infections. This study aimed at correlating these polymorphisms to lethal infections during childhood acute lymphoblastic leukemia (ALL). A matched case-control study of 34 patients who died due to infections during ALL treatment and 68 ALL patients without lethal infections was performed. Genomic DNA was isolated from blood smears and specific fragments including the polymorphic site of each gene were amplified. In the total study population, 23/102 (22.5%) of the children carried at least two variant alleles (high-producer haplotype). The variant genotypes were equally distributed between cases and controls [relative risk (RR) 1.17 (CI 0.33-2.22, P = 0.752)]. With regard to infective organisms, no statistically significant differences could be detected between the groups for bacterial infections [RR 1.59 (CI 0.56-4.50), P 0.379]. Patients with a LT-alpha (10.5 kb/5.5 kb; 5.5 kb/5.5 kb) haplotype, however, seemed to have a significant higher risk of attracting a lethal infection during induction/consolidation chemotherapy (RR 2.98, CI 0.98-9.01, P = 0.05). These results support a role of specific genetic polymorphisms on lethal infections during induction chemotherapy of ALL treatment.
肿瘤坏死因子-α(TNF-α)和淋巴毒素-α(LT-α)基因的特定突变与严重感染患者的预后相关。本研究旨在将这些多态性与儿童急性淋巴细胞白血病(ALL)期间的致命感染相关联。对34例在ALL治疗期间因感染死亡的患者和68例无致命感染的ALL患者进行了匹配病例对照研究。从血涂片中分离基因组DNA,并扩增包括每个基因多态性位点的特定片段。在整个研究人群中,23/102(22.5%)的儿童携带至少两个变异等位基因(高产单倍型)。变异基因型在病例组和对照组中分布均衡[相对风险(RR)1.17(可信区间0.33 - 2.22,P = 0.752)]。关于感染病原体,两组之间在细菌感染方面未检测到统计学显著差异[RR 1.59(可信区间0.56 - 4.50),P = 0.379]。然而,携带LT-α(10.5 kb/5.5 kb;5.5 kb/5.5 kb)单倍型的患者在诱导/巩固化疗期间发生致命感染的风险似乎显著更高(RR 2.98,可信区间0.98 - 9.01,P = 0.05)。这些结果支持特定基因多态性在ALL治疗诱导化疗期间致命感染中的作用。